Further studies are warranted to explore to what extent the increase of cell-to-cell variability in the stem cell compartment is contributing to MDS pathophysiology, as well as the specific role of the SF3B1 mutation in this process. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.